Santhera Pharmaceuticals has raised EUR 10m in a series-C financing round, with the option of calling another EUR 5m. The oversubscribed funding round was led by NGN Capital, one of Santhera's largest current shareholders. New investors to the round include NeoMed Management (Jersey), two equity funds managed by Schroder Investment Management SA (Luxembourg) and BioMedinvest (Switzerland). In addition, existing investors Carnegie Asset Management, GIMV, Dow Chemical, Clariden Biotechnology Fund, 3i and private investors supported the round.
Investindustrial sells its remaining stake of 4.12% in the company, fully exiting the investment
Following the deal, CCV Schweiz will be integrated with Concardis Schweiz, which is part of Nets Group
Minority shareholder IMS Capital has also filed for insolvency; Getnow is now seeking new investors
Exit from Rutland Fund III realises a return of 5.7x on the original cost of the investment